Featured Publications
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsTriple-negative breast cancerNon-AA patientsEvent-free survivalPhase I/II clinical trialsClinical trialsNeoadjuvant chemotherapyOverall survivalAA patientsEarly-stage triple-negative breast cancerIncidence of irAEsPathologic complete response rateSignificant associationMultivariate logistic regression analysisTumor-infiltrating lymphocyte countsComplete response ratePrimary efficacy endpointPD-L1 statusProportional hazards modelLogistic regression analysisAfrican American womenEFS ratesNeoadjuvant immunotherapyEfficacy endpointAdverse eventsClinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer
Silva S, Pereira A, Marta G, de Barros Lima K, de Freitas T, Matutino A, de Azevedo Souza M, de Azevedo R, de Viveiros P, da Silva Lima J, Filassi J, de Andrade Carvalho H, Piato J, Mano M. Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer. The Breast 2017, 38: 39-44. PMID: 29223797, DOI: 10.1016/j.breast.2017.11.012.Peer-Reviewed Original ResearchConceptsPost-operative radiation therapyDisease-free survivalBetter disease-free survivalNeoadjuvant chemotherapyBreast cancerOverall survivalAdvanced breast cancerClinical stage IIIBetter overall survivalAdvanced BC patientsTherapy delayBC patientsClinical impactEarly initiationRadiation therapyStage IIIPatientsSurgeryOptimal timingWeeksChemotherapyFirm conclusionsCancerSurvivalInitiationIntratumour heterogeneity, from hypothesis to the clinic
Shan NL, Kahn A, Pusztai L. Intratumour heterogeneity, from hypothesis to the clinic. British Journal Of Cancer 2022, 128: 459-460. PMID: 36216884, PMCID: PMC9938204, DOI: 10.1038/s41416-022-02008-w.Commentaries, Editorials and LettersStrategies to mitigate the toxicity of cancer therapeutics
Kahn AM, Blenman KRM, Sonis ST, Lustberg MB. Strategies to mitigate the toxicity of cancer therapeutics. Advances In Cancer Research 2022, 155: 215-244. PMID: 35779875, DOI: 10.1016/bs.acr.2022.02.006.Peer-Reviewed Original ResearchConceptsAromatase inhibitor-induced musculoskeletal symptomsChemotherapy-induced peripheral neuropathyCancer-related cognitive impairmentCancer treatment symptomsOral mucosal toxicityImmune checkpoint inhibitionTyrosine kinase inhibitorsCancer therapeuticsGastrointestinal toxicityMucosal toxicityAdverse eventsHormone therapySystemic therapyTreatment toxicityPeripheral neuropathyCheckpoint inhibitionSymptom managementMusculoskeletal symptomsRenal toxicityTreatment symptomsOcular toxicityTreatment modalitiesTraditional chemotherapyCognitive impairmentMonoclonal antibodiesIntratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer
Kahn A, Golestani R, Harigopal M, Pusztai L. Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer. Breast Cancer Research And Treatment 2023, 201: 289-298. PMID: 37378695, DOI: 10.1007/s10549-023-06977-1.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerPD-L1 expressionBreast cancerPD-L1Metastatic triple-negative breast cancerPD-L1 positive casesEarly-stage breast cancerPD-L1 protein expressionImmune checkpoint inhibitorsPD-L1 positivityPD-L1 statusProtein expressionWhole study populationPrimary breast tumorsNegative breast cancerConcordant negative resultsCheckpoint inhibitorsMultiple biopsiesPositive cancersCohen's kappa coefficientStudy populationE1L3N antibodyDiscordance rateBreast tumorsPositive cases
2017
Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis
Matutino A, Mak M, Takahashi T, Bitton R, Nakazato D, Fraile N, Guimarães R, Gabrielli F, Vasconcelos K, de A. Carvalho H, de Castro G. Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis. Journal Of Global Oncology 2017, 4: jgo.17.00059. PMID: 30241202, PMCID: PMC6181177, DOI: 10.1200/jgo.17.00059.Peer-Reviewed Original ResearchConceptsExtensive-stage small-cell lung cancerProphylactic cranial irradiationSmall cell lung cancerProgression-free survivalBrain metastasesOverall survivalCranial irradiationLung cancerBenefit of PCISymptomatic brain metastasesFirst-line settingSecond-line chemotherapyKaplan-Meier methodPlatinum-based chemotherapyCareful patient selectionBrain metastasis controlBaseline brainEligible patientsSystemic chemotherapyChemotherapy exposureProgressive diseasePatient selectionTherapeutic challengeDecreased incidencePatient survival
2016
Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community
Protásio B, Matutino A, Lage L, Santana I, Ramos R, Sabbaga J, Capareli F, Saragiotto D, Riechelmann R, Hoff P. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community. Clinical Colorectal Cancer 2016, 16: 65-72. PMID: 27515842, DOI: 10.1016/j.clcc.2016.07.001.Peer-Reviewed Original ResearchConceptsStage III colorectal cancerColorectal cancerClinical trialsHigh riskResected stage III colorectal cancerLogistic regression multivariate analysisStage III CRC patientsDisease-free survivalPredictors of recurrenceRegression multivariate analysisAge 70 yearsLarge cancer centerAdjuvant chemotherapyAdjuvant oxaliplatinFit patientsNeurotoxicity gradeUrgent surgeryAdjuvant regimenAdverse eventsCohort studyCommunity patientsConsecutive patientsCRC patientsMedian agePrognostic factors
2014
Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial—authors' response
Vilas-Boas A, Nascimento-Carvalho C, Matutino A, Barreto B, Silva C, Braga D, Oliveira F, Nogueira G, Oliveira Í, Lorgetto I, Costa I, Araripe J, Vieira J, Neiva L, Santana M, Nobre-Bastos M, Santos P, Câmara S, Carneiro S, Sirmos U, Araújo V, Silva C, Vilas-Boas C, Gantois D, Azevedo F, Maia J, Pirajá L, Jesus P, Fonseca T, Fontoura M, Xavier-Souza G, Araújo-Neto C, Andrade S, Brim R, Noblat L, Barral A, Cardoso M. Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial—authors' response. Journal Of Antimicrobial Chemotherapy 2014, 70: 636-638. PMID: 25362570, DOI: 10.1093/jac/dku440.Peer-Reviewed Original ResearchComparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial
Vilas-Boas A, Fontoura M, Xavier-Souza G, Araújo-Neto C, Andrade S, Brim R, Noblat L, Barral A, Cardoso M, Nascimento-Carvalho C, Matutino A, Barreto B, Silva C, Braga D, Oliveira F, Nogueira G, Oliveira Í, Lorgetto I, Costa I, Araripe J, Vieira J, Neiva L, Santana M, Nobre-Bastos M, Santos P, Câmara S, Carneiro S, Sirmos U, Araújo V, Silva C, Vilas-Boas C, Gantois D, Azevedo F, Maia J, Pirajá L, Jesus P, Fonseca T, Vilar T. Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial. Journal Of Antimicrobial Chemotherapy 2014, 69: 1954-1959. PMID: 24648506, DOI: 10.1093/jac/dku070.Peer-Reviewed Original ResearchConceptsNon-severe pneumoniaTreatment failureOral amoxicillinFirst-line therapyChildhood pneumoniaPrimary outcomeTreat analysisRespiratory complaintsBlinded investigationDaily dosesChest radiographsPatient allocationPneumoniaPatientsIndependent radiologistsAmoxicillinProtocol analysisThriceMonthsChildrenParticipantsFailureConcordant readingsPlaceboTherapy
2012
Differences in evolution of children with non-severe acute lower respiratory tract infection with and without radiographically diagnosed pneumonia
Fontoura M, Matutino A, Silva C, Santana M, Nobre-Bastos M, Oliveira F, Barreto B, Araújo-Neto C, Andrade S, Brim R, Cardoso M, Nascimento-Carvalho C, Pneumopac-Efficacy Study Group. Differences in evolution of children with non-severe acute lower respiratory tract infection with and without radiographically diagnosed pneumonia. Indian Pediatrics 2012, 49: 363-369. PMID: 22080618, DOI: 10.1007/s13312-012-0085-6.Peer-Reviewed Original ResearchConceptsAcute lower respiratory tract infectionChest X-rayLower respiratory tract infectionsRespiratory tract infectionsTract infectionsLower respiratory tract diseaseEvolution of childrenNormal chest X-rayIndependent pediatric radiologistsHigh positive predictive valueUniversity Pediatric HospitalRespiratory tract diseasePositive predictive valueAmoxicillin allergyPulmonary infiltratesPleural effusionClinical symptomsPediatric hospitalAmoxicillin treatmentResultsA totalPulmonary expansionActive surveillancePneumonia casesTract diseaseAntibiotic use
2010
Clinical failure among children with nonsevere community-acquired pneumonia treated with amoxicillin
Fontoura M, Araújo-Neto C, Andrade S, Brim R, Matutino A, Silva C, Santana M, Nobre-Bastos M, Oliveira F, Barreto B, Santos P, Noblat L, Cardoso M, Nascimento-Carvalho C, Group T. Clinical failure among children with nonsevere community-acquired pneumonia treated with amoxicillin. Expert Opinion On Pharmacotherapy 2010, 11: 1451-1458. PMID: 20408745, DOI: 10.1517/14656561003777034.Peer-Reviewed Original ResearchConceptsClinical failureDays of treatmentRisk factorsNonsevere community-acquired pneumoniaAdverse effect frequencyPersistence of feverRadiographic pulmonary infiltratesCommunity-acquired pneumoniaIndependent risk factorClinical failure rateNonsevere pneumoniaPulmonary infiltratesAdverse eventsPleural effusionRespiratory complaintsClinical findingsDifficulty breathingAdverse reactionsSevere diseasePneumonia diagnosisCystic fibrosisMultivariate analysisDemographic dataAmoxicillinOlder children